All News

vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Rituximab is not Superior in EGPA

Jack Cush, MD

A cohort study of Eosinophilic Granulomatosis With Polyangiitis (EGPA) patients from the French Vasculitis Study Group failed to show superiority of rituximab compared to conventional strategy with glucocorticoids (GS) alone or in combination with cyclophosphamide.

Read Article
glomerulonephritis.jpg

HCQ Preserves Renal Function in Lupus Nephritis

MedPage Today

Lupus nephritis patients on long-term therapy with hydroxychloroquine showed significantly less decline in renal function, compared with patients treated otherwise, a 10-year retrospective study indicated.

Read Article
Biologic.choice.MD_.jpeg (keep)

Factors Affecting Biologic Use in Rheumatoid Arthritis

Jack Cush, MD

A San Francisco Rheumatoid Arthritis Panel cohort survey between 1999–2011, showed numerous sociodemographic, disease, and health characteristics that influenced the initiation of treatment with biologic agents for rheumatoid arthritis (RA).

Read Article
RheumNow Podcast square

CKD & Osteoporosis Rx Revisited (7.25.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.

Read Article
Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors

Jack Cush, MD

Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer.

Read Article
FDA,approved,stamp,blue

Emapalumab Approved for MAS in Still’s

Susan Shenoi, MD, MS

On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with inadequate response or intolerance to glucocorticoids.

Read Article
RheumNow Podcast square

NHANES, Numbers, & Risk (7.18.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com along with interesting case questions from "Ask Cush Anything".

Read Article
Tyk2.Wikipedia

Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis

Jack Cush, MD

A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA).

Read Article
hip-fracture.jpg

Osteoporosis treatment benefits people older than 80

EurekAlert!

People who are older than 80 should be considered for osteoporosis treatment after a fracture to avoid further risk, according to a study being presented Saturday at ENDO 2025, the Endocrine Society’s annual meeting in San Francisco, Calif.

Read Article
Lung,cancer,nci

Interstitial Lung Disease and Lung Cancer Risk

Jack Cush, MD

A large prospective cohort study found that interstitial lung disease (ILD) is associated with an increased risk of lung cancer.

Read Article
RHEUM Survey: Starting a new biologic agent in RA, when do you expect to see a good response? CLICK HERE>> https://t.co/NBXu4cNLVj a.6 weeks b.3 months c.4 months d.6 months e.With adverse events

Links:

Dr. John Cush RheumNow ( View Tweet)

CKD & Osteoporosis Rx Revisited (7.25.2025) Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow. https://t.co/k78DRpWIJS https://t.co/aYKvIhmJN1

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of risankizumab efficacy & safety included 545 psoriasis pts showing Mean PASI decreased from 14 to 0.5 at 208Wk. PASI100 achieved in 33% and 74% at 16Wk & 208Wk. Bio-naïve responded faster bio-experienced pts - only 5 pts D/C for adverse events https://t.co/VklLWpD0SF https://t.co/zZfuiFijd4

Links:

Dr. John Cush RheumNow ( View Tweet)
Practical management of rheumatic immune-related adverse events with immune checkpoint inhibitors Joint Bone Spine has published a full read review of the management of immune-related adverse events (irAEs) in patients receiving Immune checkpoint inhibitors (ICIs) for cancer. https://t.co/i3FMOCbyNg
Dr. John Cush RheumNow ( View Tweet)
FDA has accepted BLA for BAT2506, a biosimilar of Simponi (golimumab) for all approved doses, formulations, & indications of reference product, with a request for interchangeability (BsUFA: May 16, 2026) https://t.co/kVFAz9ltlr https://t.co/LqdzsXlqER

Links:

Dr. John Cush RheumNow ( View Tweet)
BMS announced today that the FDA has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adult active psoriatic arthritis. The FDA decision (PDUFA) date is March 6, 2026. https://t.co/yMxkUP5FAw https://t.co/2teEUbWFem

Links:

Dr. John Cush RheumNow ( View Tweet)
Manifestations and Treatment in Relapsing Polychondritis A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease. https://t.co/Gz2qwtC4jZ https://t.co/llK9W45DlW

Links:

Dr. John Cush RheumNow ( View Tweet)
Molecular profiling of RA synovium predicts biologic responses Machine learning analysis of pre-treatment synovial tissue biopsy from RA patients starting either ETN, TCZ and RTX revealed high accuracy prediction of 16 week outcomes unique to each biologic. https://t.co/4d6NEY6JN6
Dr. John Cush RheumNow ( View Tweet)
HHS secretary Abruptly Cancels USPSTF Meeting on July 10 - to discuss diet, physical activity, and weight loss to prevent cardiovascular disease in adults. An HHS spokesperson did not give a reason. https://t.co/IqNOUWeVA4 https://t.co/0AmxQ1ZAcQ

Links:

Dr. John Cush RheumNow ( View Tweet)
CMS to Test Prior Authorization Model in Traditional Medicare The Centers for Medicare & Medicaid Services (CMS) announced a new experimental model late last week to streamline some prior authorizations under the traditional Medicare program, but some politicians and experts https://t.co/o8iV9Bb6Ir
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×